|
Antibody specificity / |
|
Substrate |
Species |
Format
|
EI 2630-9601 G |
Mumps virus |
IgG |
|
2/20/200 RU/ml |
96 x 01 |
EI 2630-9601 M |
Mumps virus incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2630-9601-3 G | Mumps virus AT: strains "Enders" and "Jeryl Lynn" |
IgG |
2/20/200 RU/ml |
96 x 01 | |
EI 2630-9601-5 M | Mumps virus G5: native antigens, genotype "G5" incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2630-9601-L G | Mumps virus antibody determination in CSF |
IgG |
5/25/50/100 U | 96 x 01 | |
FI 2630-1005 G FI 2630-1010 G FI 2630-1005 M FI 2630-1010 M FK 2630-1005 FK 2630-1010 |
Mumps virus | IgG IgM |
infected cells | EU 13 | 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides) |
FI 2822-1001-1 G FI 2822-1002-1 G FI 2822-1001-1 M * FI 2822-1002-1 M * |
Exanthema Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP,HHV-6,Rubella virus*, Measles virus,Mumps virus field B: VZV, EBV-CA, EBV-EA, Treponema pallidum field C: HSV-1 and -2, Coxsackie virus type B1 and A9 field D: Echo virus type 7, Borrelia afzelii, burgdorferi(CH),garinii field E: CMV, Candida albicans,krusei*,tropicalis* |
|
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
FI 2823-1001-1 G * FI 2823-1002-1 G * FI 2823-1001-1 M * FI 2823-1002-1 M * |
Lymphadenitis Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, HIV-1* and 2*, HHV-6, Rubella virus* field B: measles virus, Mumps virus,Adenovirus type 3,Parainfluenza virus type 1 field C: EBV-CA, EBV-EA, Toxoplasma gondii, Treponema pallidum field D: HSV-1 and -2, CMV, Coxsackie virus type B5 field E: Coxsackie virus type A9, Bartonella henselae, Chlamydia trachomatis and pneumoniae |
|
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV field B: Adenovirus type 3, EBV-CA, Treponema pallidum, Toxoplasma gondii field C: HSV-1 and -2, Coxsackie virus type B1 and A7 field D: Echo virus type 7, Borrelia afzelii, burgdorferi (CH), garinii field E: CMV, Haemophilus influenzae*, Listeria monocytogenes 1/2a and 4b |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV field B: Adenovirus type 3, EBV-CA,Treponema pallidum,Toxoplasma gondii field C: HSV-1 and -2, Coxsackie virus type B1 and A7 field D: Echo virus type 7, Borr. afzelii,burgdorferi (CH), garinii field E: CMV, Haemophilus influenzae*,Listeria monocytogenes 1/2a and 4b |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2825-1001-1 G FI 2825-1002-1 G FI 2825-1001-1 M FI 2825-1002-1 M |
Myocarditis Profile 1 (consisting of 17 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Mumps virus, Adenovirus type 3, Influenza virus type A (H1N1 and H3N2) field B: Influenza virus Typ B, Parainfluenza virus type 1 and 2, Mycoplasma pneumoniae field C: CMV, Coxsackie virus type B1 and A16, Echo virus type 7 field D: Borrelia afzelii, burgdorferi (CH),garinii, Chlamydia pneumoniae |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
CK 2630-0220-L G | CSQ pair of controls anti-Mumps virus (IgG) |
IgG | 2 x 2 ml, ready for use | ||
CI 2630-0101 G | antibodies against Mumps virus IgG positive control |
IgG | 0.1 ml | ||
CI 2630-0101 Z | Mumps virus negative control |
IgG, IgM | 0.1 ml | ||
CI 2630-0101 M | antibodies against Mumps virus IgM positive control |
IgM | 0.1 ml |
*) Currently not available as IVD in the European Union.
|
Antibody specificity / |
|
Substrate |
Species |
Format
|
EI 2630-9601 G |
Mumps virus |
IgG |
|
2/20/200 RU/ml |
96 x 01 |
EI 2630-9601 M |
Mumps virus incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2630-9601-3 G | Mumps virus AT: strains "Enders" and "Jeryl Lynn" |
IgG |
2/20/200 RU/ml |
96 x 01 | |
EI 2630-9601-5 M | Mumps virus G5: native antigens, genotype "G5" incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2630-9601-L G | Mumps virus antibody determination in CSF |
IgG |
5/25/50/100 U | 96 x 01 | |
FI 2630-1005 G FI 2630-1010 G FI 2630-1005 M FI 2630-1010 M FK 2630-1005 FK 2630-1010 |
Mumps virus | IgG IgM |
infected cells | EU 13 | 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides) |
FI 2822-1001-1 G FI 2822-1002-1 G FI 2822-1001-1 M * FI 2822-1002-1 M * |
Exanthema Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP,HHV-6,Rubella virus*, Measles virus,Mumps virus field B: VZV, EBV-CA, EBV-EA, Treponema pallidum field C: HSV-1 and -2, Coxsackie virus type B1 and A9 field D: Echo virus type 7, Borrelia afzelii, burgdorferi(CH),garinii field E: CMV, Candida albicans,krusei*,tropicalis* |
|
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
FI 2823-1001-1 G * FI 2823-1002-1 G * FI 2823-1001-1 M * FI 2823-1002-1 M * |
Lymphadenitis Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, HIV-1* and 2*, HHV-6, Rubella virus* field B: measles virus, Mumps virus,Adenovirus type 3,Parainfluenza virus type 1 field C: EBV-CA, EBV-EA, Toxoplasma gondii, Treponema pallidum field D: HSV-1 and -2, CMV, Coxsackie virus type B5 field E: Coxsackie virus type A9, Bartonella henselae, Chlamydia trachomatis and pneumoniae |
|
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV field B: Adenovirus type 3, EBV-CA, Treponema pallidum, Toxoplasma gondii field C: HSV-1 and -2, Coxsackie virus type B1 and A7 field D: Echo virus type 7, Borrelia afzelii, burgdorferi (CH), garinii field E: CMV, Haemophilus influenzae*, Listeria monocytogenes 1/2a and 4b |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV field B: Adenovirus type 3, EBV-CA,Treponema pallidum,Toxoplasma gondii field C: HSV-1 and -2, Coxsackie virus type B1 and A7 field D: Echo virus type 7, Borr. afzelii,burgdorferi (CH), garinii field E: CMV, Haemophilus influenzae*,Listeria monocytogenes 1/2a and 4b |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2825-1001-1 G FI 2825-1002-1 G FI 2825-1001-1 M FI 2825-1002-1 M |
Myocarditis Profile 1 (consisting of 17 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Mumps virus, Adenovirus type 3, Influenza virus type A (H1N1 and H3N2) field B: Influenza virus Typ B, Parainfluenza virus type 1 and 2, Mycoplasma pneumoniae field C: CMV, Coxsackie virus type B1 and A16, Echo virus type 7 field D: Borrelia afzelii, burgdorferi (CH),garinii, Chlamydia pneumoniae |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
CK 2630-0220-L G | CSQ pair of controls anti-Mumps virus (IgG) |
IgG | 2 x 2 ml, ready for use | ||
CI 2630-0101 G | antibodies against Mumps virus IgG positive control |
IgG | 0.1 ml | ||
CI 2630-0101 Z | Mumps virus negative control |
IgG, IgM | 0.1 ml | ||
CI 2630-0101 M | antibodies against Mumps virus IgM positive control |
IgM | 0.1 ml |
*) Currently not available as IVD in the European Union.